Skip to main content
Premium Trial:

Request an Annual Quote

Regulus, GSK Ink Second miRNA Rx Collaboration

Premium

Regulus Therapeutics said this week that it has formed a new collaboration with British drugs giant GlaxoSmithKline to develop drugs targeting microRNA-122, with hepatitis C infection as the lead indication for the effort.

Under the deal, Regulus will receive upfront payments and early-stage milestones, with the potential to earn more than $150 million, as well as tiered royalties up to double digits on the worldwide sale of products resulting from the alliance.

Additional terms were not disclosed.

Regulus said that it expects to have identified a miR-122-targeting clinical candidate in the second half of the year, and file an investigational new drug application in 2011.

MiR-122 is the most abundantly expressed miRNA in the liver, and has been linked to cholesterol regulation and lipid metabolism, as well as HCV replication. A number of other companies are looking to it as a therapeutic target, most notably Santaris Pharma, which recently completed a phase I study using a locked nucleic acid-based drug called SPC3649 to down-regulate the miRNA as a treatment for HCV (see RNAi News, 5/7/2009).

Notably, GlaxoSmithKline had an option to SPC3649, but let it expire last year (see RNAi News, 12/3/2009). Now, it seems, the big pharma had interest in the target, but opted to pursue it through an already-established partnership.

Regulus and GlaxoSmithKline have been working together on miRNA therapeutics since 2008, when they struck a deal in inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease (see RNAi News, 4/17/2008).

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.